SCHEMBL6433555

SCHEMBL6433555

O/N=C1/C=C(c2ccc(O)cc2O)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 2/20 0.37
CDK5 Q00535 1/20 0.37
CDK5R1 Q15078 1/20 0.37
MAOA P21397 3/20 0.33
MAOB P27338 3/20 0.33
PRKCI P41743 1/20 0.33
ESR1 P03372 3/20 0.32
ESR2 Q92731 3/20 0.32
ALDH1A1 P00352 1/20 0.32
GAA P10253 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
HTT P42858 1/20 0.32
RUNX1 Q01196 1/20 0.32
CBFB Q13951 1/20 0.32
TYR P14679 2/20 0.31
UGT1A1 P22309 1/20 0.31
HSP90AA1 P07900 1/20 0.31
PBRM1 Q86U86 1/20 0.31
EGFR P00533 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6433561 1.00 ALOX5 (0.37) ALOX5CDK5CDK5R1MAOAMAOB
SCHEMBL6433495 0.90 MAOA (0.38) ALOX5CDK5CDK5R1MAOAMAOB
SCHEMBL6433499 0.90 MAOA (0.38) ALOX5CDK5CDK5R1MAOAMAOB
SCHEMBL6433515 0.74 ESR2 (0.44) ALOX5MAOAMAOBPRKCIESR1
SCHEMBL28161627 0.69 ALOX5 (0.45) ALOX5MAOAMAOBPRKCIESR1
SCHEMBL6436211 0.68 MAOA (0.47) ALOX5MAOAMAOBPRKCIESR1
SCHEMBL278749 0.66 ALOX5 (0.62) ALOX5MAOAMAOBESR1ESR2
SCHEMBL29623114 0.66 ALOX5 (0.62) ALOX5MAOAMAOBESR1ESR2
SCHEMBL6454616 0.64 MAOA (0.40) ALOX5MAOAMAOBPRKCIESR1
SCHEMBL614590 0.63 ALOX5 (0.39) ALOX5MAOAMAOBPRKCIESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6933319-B2 Resorcinol derivatives PFIZER INC. (US) 2005-08-23 US claimed
US-6828460-B2 Containing at least one ester, oxime, sulfonamide, hydroxyamino or alkyoxyamino functionality; skin lightening agents; tyrosinase inhibitors PFIZER INC. 2004-12-07 US claimed
US-20040209949-A1 Resorcinol derivatives BROWNING ANDREW FRANCIS (SE) 2004-10-21 US claimed
US-20020161041-A1 Resorcinol derivatives PFIZER INC. 2002-10-31 US claimed
EP-1165495-A1 RESORCINOL DERIVATIVES PFIZER INC. (US) 2002-01-02 EP claimed
WO-2000056702-A1 RESORCINOL DERIVATIVES PFIZER INC. (US) 2000-09-28 WO claimed
US-6933319-B2 Resorcinol derivatives PFIZER INC. (US) 2005-08-23 US disclosed
US-20050143594-A1 Process for preparing resorcinol derivatives BRADLEY STUART E (GB) 2005-06-30 US disclosed
EP-1165495-B1 RESORCINOL DERIVATIVES PFIZER (US) 2005-04-20 EP disclosed
US-6861564-B2 Process for preparing resorcinol derivatives PFIZER INC. (US) 2005-03-01 US disclosed
US-6828460-B2 Containing at least one ester, oxime, sulfonamide, hydroxyamino or alkyoxyamino functionality; skin lightening agents; tyrosinase inhibitors PFIZER INC. 2004-12-07 US disclosed
US-20040209949-A1 Resorcinol derivatives BROWNING ANDREW FRANCIS (SE) 2004-10-21 US disclosed
US-20030088113-A1 Process for preparing resorcinol derivatives BRADLEY STUART EDWARD (GB) 2003-05-08 US disclosed
US-6504037-B2 Reacting a cyclohexanedione or chromene-one derivative with 1,8-diazabicyclo(5.4.0)undec-7ene WARNER-LAMBERT COMPANY 2003-01-07 US disclosed
US-20020161041-A1 Resorcinol derivatives PFIZER INC. 2002-10-31 US disclosed
US-20020032352-A1 Process for preparing resorcinol derivatives PFIZER PRODUCTS INC. 2002-03-14 US disclosed
EP-1165495-A1 RESORCINOL DERIVATIVES PFIZER INC. (US) 2002-01-02 EP disclosed
EP-1134207-A1 Process for preparing resorcinol derivatives Pfizer Products Inc. (US) 2001-09-19 EP disclosed
WO-2000056702-A1 RESORCINOL DERIVATIVES PFIZER INC. (US) 2000-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143594-A1 Process for preparing resorcinol derivatives CYP4B1, CYP4A11, POR ALOX5 2399/4885CDK5 3234/4885CDK5R1 3100/4885
US-20030088113-A1 Process for preparing resorcinol derivatives CYP4B1, CYP4A11, POR ALOX5 2399/4885CDK5 3234/4885CDK5R1 3100/4885
US-20040209949-A1 Resorcinol derivatives NQO1, LRAT, ALDH1A2 ALOX5 1355/4885CDK5 3733/4885CDK5R1 3397/4885
US-20020032352-A1 Process for preparing resorcinol derivatives CYP4B1, CYP4A11, POR ALOX5 2399/4885CDK5 3234/4885CDK5R1 3100/4885
US-20020161041-A1 Resorcinol derivatives NQO1, LRAT, ALDH1A2 ALOX5 1355/4885CDK5 3733/4885CDK5R1 3397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.